about
Distinct Effects of Two HIV-1 Capsid Assembly Inhibitor Families That Bind the Same Site within the N-Terminal Domain of the Viral CA ProteinIn silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.HIV-1 antiretroviral drug therapy.Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.Susan Allen: confronting HIV in Africa. Interview by Hema Bashyam.Predictive value of HIV-1 genotypic resistance test interpretation algorithms.Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.A novel method for determining the inhibitory potential of anti-HIV drugs.Mixing the right hepatitis C inhibitor cocktail.Dolutegravir: an exciting new kid on the block.Alice in microbes' land: adaptations and counter-adaptations of vector-borne parasitic protozoa and their hosts.Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure.The impact of individual human immunodeficiency virus type 1 protease mutations on drug susceptibility is highly influenced by complex interactions with the background protease sequence.The emergence of HIV-1 primary drug resistance genotypes among treatment-naïve men who have sex with men in high-prevalence areas in China.Probing Structural Changes among Analogous Inhibitor-Bound Forms of HIV-1 Protease and a Drug-Resistant Mutant in Solution by Nuclear Magnetic Resonance.Future prospects for the treatment of rapidly evolving viral pathogens: insights from evolutionary biology
P2860
Q27678471-F8D2F395-3547-4E09-B7C4-EA8467611488Q34221633-1AF4B615-A763-41D7-8516-B63FC3B3F18DQ34737547-C1E37C26-D626-4BC2-ABA1-4836310558A5Q35853012-DF2B666C-D56E-4F1C-B7F5-FD8D99B2AAA0Q36086711-999ECBEB-51B1-4F2E-B6BA-5D4208BC8A8CQ36639948-C59B7163-4D48-4451-835F-1AFDA3FFCDFEQ36641563-95FE4FAD-E58D-4C36-99ED-3A573CF4BEEDQ37454209-44405D4B-DDEE-489F-B097-D148522B2E65Q37616810-794A2ED2-20F7-4131-AC3C-C8D82F969458Q37812189-E4BC23C8-B443-4604-80D4-C809692240ABQ38180458-B0673416-5557-4E1B-8DE0-0F069F34A295Q38892717-55CA5EBC-01CE-4328-BB76-EFB48D180181Q41090342-39A9B41D-4A8D-42BA-BB82-95EF2BF42BC2Q42080184-4AE21DC9-7486-4768-BAB9-69D665820E52Q42283290-CDF13D78-5465-4F65-A70E-CEC7538E0B6CQ49851708-A72DF8F7-EDC6-429F-8180-34078D0FBA73Q56957602-8A8C7AF4-7626-4084-9EC4-DA2E6064102C
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Viral drug resistance and fitness.
@en
Viral drug resistance and fitness.
@nl
type
label
Viral drug resistance and fitness.
@en
Viral drug resistance and fitness.
@nl
prefLabel
Viral drug resistance and fitness.
@en
Viral drug resistance and fitness.
@nl
P2093
P1476
Viral drug resistance and fitness
@en
P2093
Dawn M Moore-Dudley
Eric J Arts
Miguel E Quiñones-Mateu
Oyebisi Jegede
P304
P356
10.1016/S1054-3589(07)56009-6
P50
P577
2008-01-01T00:00:00Z